Table 1.
Demographic and clinicopathologic information on the 31 INETs patients under evaluation.
| Variable | NFT | FT | p Value | |
|---|---|---|---|---|
| Age (Years) | <50 | 8 | 4 | 0.106 |
| 51–70 | 7 | 9 | ||
| >70 | 0 | 3 | ||
| Gender | Male | 13 | 12 | 0.653 |
| Female | 2 | 4 | ||
| Outcome | DOD | 5 | 8 | |
| AW | 0 | 0 | 0.3480 | |
| AWD | 7 | 3 | ||
| A.NED | 3 | 3 | ||
| Medical Treatment | SMS | 12 | 13 | |
| CT | 2 | 3 | 0.653 | |
| SMS+CT | 0 | 0 | ||
| NO | 1 | 0 | ||
| Liver Tumor Load | H1 | 13 | 1 | 0.0000026 |
| H2 | 1 | 1 | ||
| H3 | 1 | 14 | ||
| Basal CgA ng/mL | <200 | 10 | 3 | 0.0113 |
| >200 | 5 | 13 | ||
F, female; M, male; DOD, died of disease; AW, alive and well; AWD, alive with disease; A.NED, not evidence of disease; H1, liver involvement <25%; H2, liver involvement between 25 and 50%; H3, liver involvement >50%; INETs, ileal neuroendocrine tumors; SMS, somatostatin analogues; CT, chemotheraphy; CgA, chromogranin A.